Vaccine

Moderna Vaccine Trial: How Upbeat Coronavirus News Fueled a Stock Surge

When the biotech company Moderna announced early on Monday morning positive results from a small, preliminary trial of its coronavirus vaccine, the company’s chief medical officer described the news as a “triumphant day for us.”

Moderna’s stock price jumped as much as 30 percent. Its announcement helped lift the stock market and was widely reported by news organizations, including The New York Times.

Nine hours after its initial news release — and after the markets closed — the company announced a stock offering with the aim of raising more than $1 billion to help bankroll vaccine development. That offering had not been mentioned in Moderna’s briefings of investors and journalists that morning, and the company chairman later said it was decided on only that afternoon.

By Tuesday, a backlash was underway. The company had not released any more data, so scientists could not evaluate its claim. The government agency leading

Read More

Coronavirus Vaccine Shows Promising Early Results in China

A vaccine developed in China appears to be safe and may protect people from the new coronavirus, researchers reported on Friday.

The early-stage trial, published in the Lancet, was conducted by researchers at several laboratories and included 108 participants aged 18 to 60. Those who received a single dose of the vaccine produced certain immune cells, called T cells, within two weeks. Antibodies needed for immunity peaked at 28 days after the inoculation.

“This is promising data, but it’s early data,” said Dr. Dan Barouch, director of vaccine research at Beth Israel Deaconess Medical Center in Boston, who was not involved in the work. “Over all, I would say this is good news.”

The trial is the first step in testing the vaccine and was intended mainly to verify its safety. Proof of its effectiveness will require trials in thousands, perhaps hundreds of thousands, more people.

A vaccine for

Read More

Polio and Measles Could Surge After Disruption of Vaccine Programs

The widespread interruption of routine immunization programs around the world during the coronavirus pandemic is putting 80 million children under 1 year old at risk of contracting deadly, vaccine-preventable diseases, according to a report Friday by the World Health Organization, UNICEF and Gavi, the Vaccine Alliance.

The groups surveyed 129 poor and middle-income countries and found that 68 had some degree of disruption of vaccine services through clinics and through large inoculation campaigns.

Measles initiatives, for example, have been suspended in 27 countries, including Chad and Ethiopia, and polio programs are on hold in 38, including Pakistan and the Democratic Republic of Congo.

Many public health experts say they are worried that deaths from diseases including cholera, rotavirus and diphtheria could far outstrip those from Covid-19 itself.

The report highlighted warnings about polio, which had recently been all but eradicated, a hard-won victory that resulted from mass immunization programs that

Read More

$1.2 Billion From U.S. to Drugmaker to Pursue Coronavirus Vaccine

The deal with AstraZeneca is the fourth and by far the largest vaccine research agreement that the department has disclosed. The money will pay for a Phase 3 clinical trial of a potential vaccine in the United States this summer with about 30,000 volunteers.

The H.H.S. statement said the agency and AstraZeneca “are collaborating to make available at least 300 million doses,” and projected that the first doses could be available as early as October.

There is no proven treatment or vaccine against the virus, and infectious-disease experts also warn that many vaccine candidates take years to perfect. Some fail or cause such severe side effects that human trials are halted.

But even before any are approved, governments and other organizations like the Bill & Melinda Gates Foundation are spending millions of dollars to prepare for the manufacturing of several potential vaccines to make them broadly available as soon as

Read More